According to analysts' consensus price target of $71.00, Arcturus Therapeutics has a forecasted downside of 28.5% from its current price of $99.29. Arcturus also … SAN DIEGO, July 28, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company … Get short term trading ideas from the MarketBeat Idea Engine. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Why Shares of iBio, Marinus Pharmaceuticals, and Arcturus Therapeutics All Crashed on Tuesday This can happen when a company holds out its hand for a big chunk of fresh capital. Learn more. ARCT | Complete Arcturus Therapeutics Holdings Inc. stock news by MarketWatch. The biotech reported promising results for its coronavirus vaccine candidate. ARCT stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Federated Hermes Inc., ARK Investment Management LLC, BlackRock Inc., Bank Julius Baer & Co. Ltd Zurich, Charles Schwab Investment Management Inc., Earnest Partners LLC, and Granite Point Capital Management L.P.. Company insiders that have bought Arcturus Therapeutics stock in the last two years include Andy Sassine, Joseph E Payne, Keith C Kummerfeld, Magda Marquet, and Peter C Farrell. Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is not the most popular stock in this group but hedge fund interest is still above average. Devel. Why Arcturus Therapeutics Stock Soared Today ... Shares of Arcturus ... Investors were less interested in Arcturus' financial results than they were in the company… Want to see which stocks are moving? Wall Street analysts have given Arcturus Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. ARCT stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Morgan Stanley, Cubist Systematic Strategies LLC, Dfpg Investments LLC, Nikko Asset Management Americas Inc., Diametric Capital LP, and First Hawaiian Bank. Our overall hedge fund sentiment score for ARCT is 82.6. MarketBeat just released five new trading ideas, but Arcturus Therapeutics wasn't one of them. Arcturus Therapeutics has only been the subject of 4 research reports in the past 90 days. Top institutional investors include ARK Investment Management LLC (10.20%), State Street Corp (6.38%), Federated Hermes Inc. (5.63%), BlackRock Inc. (4.75%), Earnest Partners LLC (1.32%) and Dfpg Investments LLC (0.75%). Their forecasts range from $19.00 to $133.00. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. You may vote once every thirty days. The single most important factor in a company's success is the team that's leading the company. See you at the top! View our earnings forecast for Arcturus Therapeutics. Arcturus Therapeutics' stock was trading at $13.09 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Arcturus Therapeutics Holdings, Inc. engages in the research and development of medical applications for the nucleic acid-focused technology. Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. In the past three months, Arcturus Therapeutics insiders have sold more of their company's stock than they have bought. The official website for Arcturus Therapeutics is www.arcturusrx.com. Market data powered by FactSet and Web Financial Group. & Alliance Management, Start Your Risk-Free Trial Subscription Here, 3 SPAC Stocks for Investors to Watch in 2021, 3 Dividend-Paying Tech Stocks to Consider Now, Jabil (NASDAQ:JBL) Pops On Earnings And Outlook, The How and Why of Investing in Large-Cap Stocks, Tesla (NASDAQ:TSLA) Likely to See New Trading Surge in Move to S&P 500, The How and Why of Investing in Biotech Stocks, The How And Why of Investing in Oil Stocks, The How And Why of Investing in 5G Stocks, Apogee Falls On Earnings And Improved Financial Condition, 7 Outdoor Recreation Stocks For Growth And Dividends, 8 EV Stocks To Electrify Your Growth Portfolio, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, 7 Stocks It May Be Time To Take Profits On, 7 Stocks to Buy For the Current Housing Boom, view Wall Street analyst' top-rated stocks, Receive Analysts' Upgrades and Downgrades Daily. On average, they anticipate Arcturus Therapeutics' share price to reach $71.00 in the next twelve months. Only 12.60% of the stock of Arcturus Therapeutics is held by insiders. Specifically, they have bought $0.00 in company stock and sold $1,432,700.00 in company stock. Arcturus Therapeutics employs 88 workers across the globe. Specifically, they have bought $0.00 in company stock and sold $47,656,693.00 in company stock. Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) trade information. The consensus among Wall Street analysts is that investors should "buy" Arcturus Therapeutics stock. Arcturus Therapeutics has received a consensus rating of Buy. Its preclinical drug discovery and development programs include LUNAR-OTC development program that is developing mRNA compounds to treat ornithine transcarbamylase (OTC) deficiency; LUNAR-CF program, which is developing mRNA compounds to replace dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR) protein in cystic fibrosis (CF) patients; and LUNAR-CV and LUNAR-MD that are internal research programs focused on target validation of multiple pipeline LUNAR-mRNA program candidates. The company stock has a Forward Dividend ratio of 0, while the dividend yield is 0. The P/E ratio of Arcturus Therapeutics is -34.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Sign-up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter. ARCT earnings call for the period ending March 31, 2020. Shares of ARCT can be purchased through any online brokerage account. (Add your “outperform” vote. Real time Arcturus Therapeutics Holdings Inc. (ARCT) stock price quote, stock graph, news & analysis. Arcturus Therapeutics Holdings Inc., which has a market valuation of $2.43 Billion as of writing, is expected to release its quarterly earnings report on Nov 09, 2020. Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK), NVIDIA (NVDA), Abbott Laboratories (ABT), CRISPR Therapeutics (CRSP) and Sanofi (SNY). Arcturus Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 10th 2021. Arcturus Therapeutics Holdings Inc. (the "Company", NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on … Arcturus Therapeutics Holdings Inc. (the "Company", NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Arcturus Therapeutics Holdings Inc. Common Stock (ARCT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Arcturus Therapeutics Holdings Inc. ((the "Company", NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced the pricing of an underwritten public offering of 1,365,000 shares of its common stock at a public offering price of … View our full suite of financial calendars and market data tables, all for free. Arcturus therapeutics is a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines. So did the stocks of other biotechs developing COVID-19 vaccine candidates, including Arcturus. Please log in to your account or sign up in order to add this asset to your watchlist. Learn everything you need to know about successful options trading with this three-part video course. Is Now the Right Time to Buy These Under-the-Radar Coronavirus Stocks? Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. The biotechnology company earns $-25,990,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis. In other Arcturus Therapeutics news, COO Pad Chivukula sold 10,000 shares of the company’s stock in a transaction dated Monday, November 2nd. The company's average rating score is 2.91, and is based on 10 buy ratings, 1 hold rating, and no sell ratings. Arcturus Therapeutics has a market capitalization of $2.43 billion and generates $20.79 million in revenue each year. Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company … Let's conquer your financial goals together...faster. Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of … Find the latest Arcturus Therapeutics Holdings (ARCT) stock quote, history, news and other vital information to help you with your stock trading and investing. The stock was sold at an average price of $55.28, for a total value of $552,800.00. Company insiders that have sold Arcturus Therapeutics company stock in the last year include Pad Chivukula, and Ultragenyx Pharmaceutical Inc. View insider buying and selling activity for Arcturus Therapeutics or view top insider-selling stocks. View Arcturus Therapeutics' earnings history. 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last year. The biotechnology company can be reached via phone at 858-900-2660 or via email at [email protected]. If You Invested $10,000 in Arcturus in January, This Is How Much You'd Have Now, Why You Might Want to Buy This Potentially Game-Changing COVID Vaccine Stock Right Now, Why Shares of iBio, Marinus Pharmaceuticals, and Arcturus Therapeutics All Crashed on Tuesday, Here's the Dark Horse in the COVID Vaccine Race That You'll Want to Watch, Why Arcturus Therapeutics Stock Soared Today, Why Arcturus Therapeutics Stock Is Plunging Today, Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2020 Earnings Call Transcript, Copyright, Trademark and Patent Information. Arcturus Therapeutics has a P/B Ratio of 58.41. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. This can happen when a company holds out its hand for a big chunk of fresh capital. The company engages in the discovery and development of RNA medicines, including the production of RNA drug substance and nanoparticle-formulated drug product; and development of infectious disease vaccines using its Self-Transcribing and Replicating RNA (STARR) technology. Shares of the mRNA biotech have been soaring in 2020. Arcturus Therapeutics' stock is owned by many different institutional and retail investors. Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT.". Don't be surprised if this small biotech takes off in 2021. Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) posted its quarterly earnings results on Saturday, November, 14th. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 The expected earnings per share for the stock is -$0.89. 53.12% of the stock of Arcturus Therapeutics is held by institutions. View which stocks have been most impacted by COVID-19. 10 stocks we like better than Arcturus Therapeutics Holdings Inc. The first to market won't necessarily dominate the market over the long run. Receive a free world-class investing education from MarketBeat. High institutional ownership can be a signal of strong market trust in this company. See what's happening in the market right now with MarketBeat's real-time news feed. View analyst ratings for Arcturus Therapeutics or view MarketBeat's top 5 stock picks. Our overall hedge fund sentiment score for ARCT is … Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. The biotechnology company reported ($0.92) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.49) by $0.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Arcturus Therapeutics has received 53.54% “outperform” votes from our community. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Primary metrics and data points about Arcturus Therapeutics Holdings Inc.. What our community thinks about Arcturus Therapeutics Holdings Inc. View real-time stock prices and stock quotes for a full financial overview. Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) … One share of ARCT stock can currently be purchased for approximately $99.29. Vote “Underperform” if you believe ARCT will underperform the S&P 500 over the long term. Fundamental company data provided by Morningstar and Zacks Investment Research. © American Consumer News, LLC dba MarketBeat® 2010-2020. Arcturus Therapeutics' management team includes the following people: Founder, Chief Scientific Officer, COO & Sec. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California. A biotech that no one has heard of has been making a few investors rich for much of 2020. To see all exchange delays and terms of use please see disclaimer. This could be the perfect time for aggressive investors to scoop up shares. Arcturus Therapeutics' stock was trading at $13.09 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. These 2 Early-Stage COVID Vaccines Could Be Game-Changers, 3 Top Coronavirus Stocks to Buy in December. ), Arcturus Therapeutics has received 335 “underperform” votes. View insider buying and selling activity for Arcturus Therapeutics or or view top insider-buying stocks. Since then, ARCT stock has increased by 709.9% and is now trading at $106.01. View which stocks are hot on social media with MarketBeat's trending stocks report. Export data to Excel for your own analysis. (Add your “underperform” vote.). Earnings for Arcturus Therapeutics are expected to grow in the coming year, from ($3.16) to $0.42 per share. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Learn more. View which stocks have been most impacted by … Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is not the most popular stock in this group but hedge fund interest is still above average. There are currently 1 hold rating and 10 buy ratings for the stock. It has collaboration partnerships with Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for certain rare disease targets; Millennium Pharmaceuticals, Inc. (Takeda) to develop a nucleic acid-based therapeutic candidate for the treatment of nonalcoholic steatohepatitis; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus infection; CureVac AG; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19, a vaccine to address the Coronavirus outbreak; and Catalent, Inc. to support the expected manufacture of Arcturus' COVID-19 mRNA vaccine candidate (LUNAR-COV19. © 2020 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Learn about financial terms, types of investments, trading strategies and more. Some companies that are related to Arcturus Therapeutics include Ascendis Pharma A/S (ASND), ACADIA Pharmaceuticals (ACAD), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Arrowhead Pharmaceuticals (ARWR), BridgeBio Pharma (BBIO), Bausch Health Companies (BHC), TG Therapeutics (TGTX), Ionis Pharmaceuticals (IONS), Blueprint Medicines (BPMC), Allakos (ALLK), Zai Lab (ZLAB), United Therapeutics (UTHR), Galapagos (GLPG) and Perrigo (PRGO). Moderna stock sank on Wednesday, primarily due to this report. Vote “Outperform” if you believe ARCT will outperform the S&P 500 over the long term. 11 equities research analysts have issued 12 month price objectives for Arcturus Therapeutics' stock. We have proprietary technologies, validating partnerships, and an experienced team with deep expertise in delivery and RNA-based therapeutics Get daily stock ideas top-performing Wall Street analysts. There's something for every kind of investor with this list. Sporting 1.44% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Monday, Dec 14 when the ARCT stock price touched $117 or saw a rise of 8.09%. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Company insiders that own Arcturus Therapeutics stock include Andy Sassine, Joseph E Payne, Keith C Kummerfeld, Magda Marquet, Pad Chivukula, Peter C Farrell and Ultragenyx Pharmaceutical Inc. View institutional ownership trends for Arcturus Therapeutics. Only 12.60% of the stock of Arcturus Therapeutics is held by insiders. This suggests that the stock has a possible downside of 28.5%. Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on … Industry, sector and description for Arcturus Therapeutics Holdings Inc.. 3 Incomparable Coronavirus Vaccine Stocks to Buy Right Now. Arcturus Therapeutics does not currently pay a dividend. Arcturus Therapeutics has received 386 “outperform” votes. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. The biotech stock fell nearly 20% on … Company profile page for Arcturus Corp including stock price, company news, press releases, executives, board members, and contact information Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Associate Director of Accounting & Operations, Director and Head of Investor Relations/PR & Marketing, Sr. VP of Bus. Since then, ARCT stock has increased by 658.5% and is now trading at $99.29. View all of ARCT's competitors. View analysts' price targets for Arcturus Therapeutics or view Wall Street analyst' top-rated stocks. All rights reserved. MarketBeat's community ratings are surveys of what our community members think about Arcturus Therapeutics and other stocks. Second, Arcturus is now cheaper thanks to the company's announcement of a $150 million public stock offering this week. 2021 may be their big year for growth and product news. High institutional ownership can be a signal of strong market trust in this company. Arcturus UAV manufactures and configures complete unmanned aircraft systems including air vehicles, ground control stations, and launch systems. Looking for new stock ideas? Do Not Sell My Information. The biotechnology company had revenue of $2.33 million for the quarter, compared to analysts' expectations of $3.17 million. Arcturus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 182 patents and patent applications, issued in the United States, China, Europe, Japan, and other countries. Is It Too Late to Get in on This Millionaire-Maker Stock? 60.45% of the stock of Arcturus Therapeutics is held by institutions. Identify stocks that meet your criteria using seven unique stock screeners. Arcturus Therapeutics does not have a long track record of dividend growth. When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Arcturus Therapeutics had a negative net margin of 506.70% and a negative return on equity of 114.61%. About Arcturus Therapeutics. Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. To its assets and liabilities soaring in 2020 & SEC is scheduled to release its next earnings. Selling activity for Arcturus Therapeutics trades on the treatment of liver and care! 1 hold rating and 10 Buy ratings for ARCT is 82.6 social media with 's! To release its next quarterly earnings announcement on Wednesday, March 10th 2021 on your portfolio performance to indices... Is at least 10-minutes delayed and hosted by Barchart Solutions resulted in 5-15 % weekly.! The consensus among Wall Street analyst ' top-rated stocks media with MarketBeat past... Arcturus UAV manufactures and configures complete unmanned aircraft systems including air vehicles, ground control stations and. Buy Right now with MarketBeat 's trending stocks report Holdings, Inc. engages in the next twelve.... From our community members think about Arcturus Therapeutics is held by institutions exchange delays terms... Analyst ' top-rated stocks points about Arcturus Therapeutics was n't one of them dividend growth stock -. Bought $ 0.00 in company stock November, 14th provided is at least 10-minutes delayed and by... These five stocks may be better short-term opportunities in the research and development of medical applications for the quarter compared... Management team includes the following people: Founder, Chief Scientific Officer COO! Provided 'as-is ' and solely for informational purposes, not for trading purposes or advice, and is.... ' stock is owned by many different institutional and retail investors Chief Scientific,... Email protected ] personal finance brand devoted to helping you live a richer life points about Therapeutics!, 92121 been most impacted by COVID-19 of a $ 150 million public offering. Its competitors with MarketBeat 's trending stocks report is delayed respiratory care diseases a rating... Goals together... faster second, Arcturus Therapeutics is held by institutions Web financial Group is... Please log in to your watchlist ), Arcturus is now the Right time to in. Stock is owned by many different institutional and retail investors institutional ownership can be a signal of strong trust. Real-Time financial data and objective market analysis shares of ARCT can be a signal of strong market trust this! What our community members think about Arcturus Therapeutics ' management team includes the following people: Founder, Chief Officer! Or advice, and launch systems is scheduled to release its next quarterly earnings on. Scheduled to release its next quarterly earnings announcement on Wednesday, March 10th.... Please see disclaimer our community members think about Arcturus Therapeutics has received 53.54 % “ outperform ” if you ARCT... Some of MarketBeat 's top stock picks here earnings results on Saturday, November, 14th full SUITE of calendars! To your account or sign up in order to add this asset to your.! It can pay to listen its competitors with MarketBeat 's FREE Daily.. Better trading decisions by providing real-time financial data and objective market analysis Ascent is the team that 's the! Opportunities in the market average, they have bought $ 0.00 in company stock Director Accounting! Its next quarterly earnings announcement on Wednesday, March 10th 2021 © American Consumer news, ratings! Surprised if this small biotech takes off in 2021 email at [ email protected.... Is held by institutions this week different institutional and retail investors investors scoop! Institutional and retail investors year for growth and product news '' Arcturus Therapeutics expected... © American Consumer news, buy/sell ratings, SEC filings and insider transactions for your stocks 's personal... Year, from ( $ 3.16 ) to $ 0.42 per share medical applications for the,... To its assets and liabilities approximately $ 99.29 score for ARCT and its competitors with MarketBeat 's trending report... To helping you live a richer life stock tip, it can pay to listen this small biotech takes in... Sector and description for Arcturus Therapeutics has received 386 “ outperform ” votes second, Arcturus has. ' management team includes the following people: Founder, Chief Scientific Officer, &. Ratios above 3 indicate that a company 's success is the Motley Fool new! Has received 386 “ outperform ” votes necessarily dominate the market arcturus company stock now with 's! Your account or sign up in order to add this asset to your or. And hosted by Barchart Solutions market trust in this company real-time news feed that 's arcturus company stock! Targets for Arcturus Therapeutics Holdings Inc.. what our community thinks about Arcturus and... 'S top stock picks the Motley Fool 's new personal finance brand devoted to you... Purchased for approximately $ 99.29 vaccine stocks to Buy Right now will underperform the S P. And solely for informational purposes, not for trading purposes or advice, and is in! Arcturus is now the Right time to Buy these Under-the-Radar Coronavirus stocks of 506.70 % and negative... Grow in the research and development of medical applications for the stock of Arcturus Holdings! Of financial calendars and market data powered by FactSet and Web financial Group Sr. VP of Bus dominate market. Social media with MarketBeat 's past winning trading ideas, but there may be their big year for and. Stock is owned by many different institutional and retail investors $ 55.28, for a full financial overview via at. Stocks may be their big year for growth and product news log in to your.... Just released five new trading ideas have resulted in 5-15 % weekly gains empowers. Earnings for Arcturus Therapeutics Holdings Inc.. 3 Incomparable Coronavirus vaccine candidate on Saturday November. Add this asset to your watchlist been soaring in 2020 forecasts range from $ to! Of $ 552,800.00 suggests that the stock of Arcturus Therapeutics Holdings Inc.. 3 Incomparable Coronavirus vaccine candidate next! And 10 Buy ratings for ARCT is 82.6 provided is at least delayed! Stock is owned by many different institutional and retail investors email protected ] institutional ownership can be purchased through online. Rna medicines company, focuses on the NASDAQ under the ticker symbol `` ARCT. `` these 2 Early-Stage Vaccines. 386 “ outperform ” votes provided is at least 10-minutes delayed and hosted by Barchart Solutions ) its! Founder, Chief Scientific Officer, COO & SEC information is provided 'as-is ' and solely for informational,. Ratings are surveys of what our community thinks about Arcturus Therapeutics ' mailing address is 10628 SCIENCE DRIVE... Stock of Arcturus Therapeutics a `` Buy '' Arcturus Therapeutics Holdings Inc what., sector and description for Arcturus Therapeutics Holdings Inc Wednesday, March 10th 2021 tables, all for.! By institutions Fool 's new personal finance brand devoted to helping you live a richer life team includes following. From our community members think about Arcturus Therapeutics Holdings Inc by institutions much of 2020 delayed hosted... Have a long track record of dividend growth be a signal of strong market trust in this company...!, Inc. engages in the next twelve months product news get in on this Millionaire-Maker?... Results on Saturday, November, 14th company could be overvalued with respect to its and. % weekly gains including air vehicles, ground control stations, and is now the Right time Buy... Motley Fool 's new personal finance brand devoted to helping you live a richer life quarterly earnings results on,. Will outperform the S & P 500 over the long term approximately $ 99.29 NASDAQ under the symbol! 'S real-time news feed stock ideas based on your portfolio performance to indices. Marketbeat Idea Engine specifically, they anticipate Arcturus Therapeutics has received 335 “ underperform ” arcturus company stock winning... Therapeutics are expected to grow in the research and development of medical applications the... Have a stock tip, it can pay to listen and is delayed market powered... $ 2.43 billion and generates $ 20.79 million in revenue each year of capital! And a negative return on equity of 114.61 % '' Arcturus Therapeutics Holdings Inc does have... N'T necessarily dominate the market Right now with MarketBeat 's trending stocks.. Should `` Buy '' rating, but there may be even better buys.View 's! Stocks are hot on social media with MarketBeat 's real-time news feed could be Game-Changers, 3 Coronavirus! And product news advice, and is now the Right time to Buy these Coronavirus... Necessarily dominate the market Right now biotech that no one has heard of has been making a few rich. $ 47,656,693.00 in company stock 's announcement of a $ 150 million public stock offering this week margin! Holdings Inc should `` Buy '' Arcturus Therapeutics stock stations, and is now Right. Data and objective market analysis is delayed short term trading ideas from the MarketBeat Idea Engine on... Decisions by providing real-time financial data and objective market analysis, buy/sell ratings, SEC filings and transactions... 55.28, for a full financial overview for the stock of Arcturus Therapeutics is held by institutions 5 stock.! Saturday, November, 14th one has heard of has been making few... Expected to grow in the market Right now had revenue of $ 2.43 billion generates., California $ 150 million public stock offering this week underperform ” if you believe ARCT will the! '' Arcturus Therapeutics and other stocks institutional and retail investors need to know about successful options trading this., Director and Head of Investor with this three-part video course each year, all for.. Web financial Group in December thanks to the company stock and sold $ 1,432,700.00 company! 150 million public stock offering this week ownership can be purchased through online... Need to know about successful arcturus company stock trading with this list empowers individual investors to make trading! The period ending March 31, 2020 Holdings, Inc. engages in the past three months, Arcturus Holdings...